Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic
effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in
combination with atezolizumab or other immune checkpoint inhibitors in HLA-A*02+ patients
with recurrent, locally advanced or metastatic human papillomavirus strain 16 positive
(HPV16+) solid tumors. The study includes patients with anal, rectal, cervical, head and
neck, penile, vulvar, or vaginal cancer.